Shin Hyeong Chan, Lee Hye Won, Shin So-Jin, Kwon Sun Young
Department of Pathology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea.
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea.
Diagnostics (Basel). 2025 Jun 3;15(11):1426. doi: 10.3390/diagnostics15111426.
RNA-binding motif protein 3 (RBM3) is a cold-shock protein associated with a favorable prognosis in various malignancies. However, its role in epithelial ovarian cancer (OC) remains unclear. This study aimed to evaluate the prognostic significance of RBM3 expression in OC and its association with clinicopathological features. We retrospectively analyzed 183 cases of OC. Tissue microarrays were constructed using paired 2 mm tumor cores, and RBM3 expression was assessed by immunohistochemistry. Nuclear staining was semi-quantitatively scored based on intensity and proportion, generating a nuclear score (NS). Cases were classified as high (NS > 1) or low (NS ≤ 1) expression. Associations with clinicopathological parameters and survival outcomes were analyzed using chi-square tests, Kaplan-Meier survival curves, and Cox regression models. High RBM3 expression was observed in 51.4% of cases and was significantly associated with favorable histologic subtypes (mucinous, endometrioid, clear cell), early International Federation of Gynecology and Obstetrics (FIGO) stage, and the absence of distant metastasis. Subgroup survival analyses stratified by histologic subtype revealed no significant differences in survival outcomes. RBM3 expression was correlated with prolonged disease-free and overall survival, although it did not retain significance in multivariate analysis. RBM3 expression is strongly associated with favorable pathological features in epithelial ovarian cancer. Although not an independent prognostic marker, RBM3 may serve as a complementary biomarker for risk stratification and prognosis in clinical practice.
RNA结合基序蛋白3（RBM3）是一种冷休克蛋白，与多种恶性肿瘤的良好预后相关。然而，其在上皮性卵巢癌（OC）中的作用仍不清楚。本研究旨在评估RBM3表达在上皮性卵巢癌中的预后意义及其与临床病理特征的关系。我们回顾性分析了183例上皮性卵巢癌病例。使用配对的2毫米肿瘤核心构建组织微阵列，并通过免疫组织化学评估RBM3表达。根据强度和比例对细胞核染色进行半定量评分，得出细胞核评分（NS）。病例分为高表达（NS>1）或低表达（NS≤1）。使用卡方检验、Kaplan-Meier生存曲线和Cox回归模型分析与临床病理参数和生存结果的相关性。51.4%的病例观察到RBM3高表达，且与良好的组织学亚型（黏液性、子宫内膜样、透明细胞）、早期国际妇产科联盟（FIGO）分期以及无远处转移显著相关。按组织学亚型分层的亚组生存分析显示生存结果无显著差异。RBM3表达与无病生存期和总生存期延长相关，尽管在多变量分析中其无统计学意义。RBM3表达与上皮性卵巢癌的良好病理特征密切相关。虽然不是独立的预后标志物，但RBM3可作为临床实践中风险分层和预后的补充生物标志物。
